Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism. 1984

G Alván, and M Grind, and C Graffner, and F Sjöqvist

The metabolism of the new reversible A-selective monoamine oxidase inhibitor amiflamine was studied in relation to polymorphic hydroxylation of debrisoquine in 24 healthy subjects. Amiflamine is metabolized by two consecutive N-demethylations. By construction of urinary recovery ratios analogous to that of debrisoquine/4-hydroxydebrisoquine, correlations between debrisoquine metabolic ratio and amiflamine/demethylated metabolites were significant and consistent within slow and rapid hydroxylators of debrisoquine. It is concluded that debrisoquine hydroxylation and amiflamine N-demethylation might be under common genetic regulation.

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008297 Male Males
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D003647 Debrisoquin An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism. Debrisoquine,Tendor
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006900 Hydroxylation Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed) Hydroxylations
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.

Related Publications

G Alván, and M Grind, and C Graffner, and F Sjöqvist
March 1989, Lancet (London, England),
G Alván, and M Grind, and C Graffner, and F Sjöqvist
June 1985, British journal of clinical pharmacology,
G Alván, and M Grind, and C Graffner, and F Sjöqvist
November 1990, Diabetes research (Edinburgh, Scotland),
G Alván, and M Grind, and C Graffner, and F Sjöqvist
October 1983, Clinical pharmacology and therapeutics,
G Alván, and M Grind, and C Graffner, and F Sjöqvist
December 1989, British journal of clinical pharmacology,
G Alván, and M Grind, and C Graffner, and F Sjöqvist
August 1981, Clinical pharmacology and therapeutics,
G Alván, and M Grind, and C Graffner, and F Sjöqvist
February 1993, Pharmacology & toxicology,
G Alván, and M Grind, and C Graffner, and F Sjöqvist
November 1988, British journal of clinical pharmacology,
G Alván, and M Grind, and C Graffner, and F Sjöqvist
June 1994, Pharmacogenetics,
G Alván, and M Grind, and C Graffner, and F Sjöqvist
June 1959, Experientia,
Copied contents to your clipboard!